DrugPatentWatch Database Preview

Doxazosin mesylate - Generic Drug Details

  Purchase this report

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for doxazosin mesylate and what is the scope of doxazosin mesylate freedom to operate?

Doxazosin mesylate is the generic ingredient in three branded drugs marketed by Pfizer, Accord Hlthcare, Actavis Elizabeth, Ani Pharms Inc, Apotex, Appco Pharma Llc, Dava Pharms Inc, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Mylan, Nesher Pharms, Pliva, Teva, Watson Labs Inc, Yaopharma Co Ltd, and Zydus Pharms Usa Inc, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for doxazosin mesylate. Thirty-six suppliers are listed for this compound.

Summary for doxazosin mesylate

US Patents:	0
Tradenames:	3
Applicants:	17
NDAs:	19
Drug Master File Entries:	14
Suppliers / Packagers:	36
Bulk Api Vendors:	69
Clinical Trials:	2
Patent Applications:	2,572
Formulation / Manufacturing:	see details
DailyMed Link:	doxazosin mesylate at DailyMed

Pharmacology for doxazosin mesylate

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Medical Subject Heading (MeSH) Categories for doxazosin mesylate

Adrenergic alpha-1 Receptor Antagonists

Antihypertensive Agents

Synonyms for doxazosin mesylate

(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone methanesulfonate

[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; methanesulfonic acid

[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-2-yl)methanone; methanesulfonic acid

[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; methanesulfonic acid

[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone;methanesulfonic acid

1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(1,4-BENZODIOXAN-2-YLCARBONYL) PIPERAZINE METHANESULFONATE

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazine monomethanesulfonate

1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzoldioxan-2-ylcarbonyl)piperazine methanesulfonate

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(1,4-benzodioxan-2-yl)carbonyl]piperazine Methanesulfonate

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate

2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; methanesulfonic acid

2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine mesylate

2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; methanesulfonic acid

4-Amino-2-[4-(1,4-benzodioxan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazoline methanesulfonate

74191-85-8 (Parent)

77883-43-3

91D858

AB0008587

AB2000045

AC-6848

AC1L1Y5G

AC1Q4GSV

AC1Q4GT3

AKOS015895371

Alfadil

AN-9627

ANW-42738

Benur

Bio-0889

C23H25N5O5.CH4O3S

C24H29N5O8S

Cardenalin

Cardoral

Cardoxan

Cardular

Cardular PP

Cardular Uro

Cardura

Cardura (TN)

Cardura XL

Cardura;Carduran;Cardura XL

Carduran

Carduran Neo

CAS-77883-43-3

CCG-213583

CHEBI:4709

CHEMBL1200561

CPD000058441

CS-1830

CTK7B4527

D 9815

D00608

D4126

Dedralen

Diblocin

Diblocin PP

Diblocin Uro

Doksura

Dosin

Doxaben

Doxazocine

Doxazomerck

Doxazosin (mesylate)

Doxazosin AZU

Doxazosin mesilate

Doxazosin mesilate (JP17)

Doxazosin mesilate, European Pharmacopoeia (EP) Reference Standard

Doxazosin mesylate (USAN)

Doxazosin mesylate [USAN:USP]

Doxazosin mesylate [USAN]

Doxazosin mesylate, >=97% (HPLC), powder

Doxazosin mesylate, United States Pharmacopeia (USP) Reference Standard

DOXAZOSIN; METHANESULFONIC ACID

Doxazosinmesylate

Doxolbran

DR003231

DSSTox_CID_25598

DSSTox_GSID_45598

DSSTox_RID_80991

DTXSID5045598

Duracin

EN300-53021

EU-0100474

FT-0625592

HMS1570L17

HMS2093J14

HMS2097L17

HMS2230L18

HMS3261O10

HMS3372C03

HMS3654J15

HSDB 7082

HY-B0098A

I06-0611

J10294

Kaltensif

KS-1052

LP00474

LS-110229

MFCD00216023

MLS000028455

MLS000120399

MLS001148153

MLS002222292

MLS006011977

MolPort-003-983-427

NCGC00016146-02

NCGC00017136-01

NCGC00018158-09

NCGC00093884-01

NCGC00261159-01

NE52844

Normathen

NSC-759284

NSC759284

Opera_ID_1881

Pharmakon1600-01505976

Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-, monomethanesulfonate

Prestwick_1026

Progandol

Prostadilat

PubChem2385

RW2756

s1324

SAM002589903

SCHEMBL42621

SMR000058441

SR-01000003045

SR-01000003045-2

Supressin

Tensiobas

TL8005338

Tonocardin

Tox21_110796

Tox21_110796_1

Tox21_500474

UK 33,274-27

UK-33,274-27

UK-33274-27

UK-3327427

VJECBOKJABCYMF-UHFFFAOYSA-N

Z1259084903

US Patents and Regulatory Information for doxazosin mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	DOXAZOSIN MESYLATE	doxazosin mesylate	TABLET;ORAL	075580-004	Oct 18, 2000	AB	RX	No	No
Teva	DOXAZOSIN MESYLATE	doxazosin mesylate	TABLET;ORAL	075353-001	Jan 12, 2001		DISCN	No	No
Teva	DOXAZOSIN MESYLATE	doxazosin mesylate	TABLET;ORAL	075353-003	Jan 12, 2001		DISCN	No	No
Genpharm	DOXAZOSIN MESYLATE	doxazosin mesylate	TABLET;ORAL	075466-001	Oct 18, 2000		DISCN	No	No

  Purchase this report

see a sample report or, see our see our flat-rate plans

Expired US Patents for doxazosin mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-004	Nov 2, 1990
Pfizer	CARDURA XL	doxazosin mesylate	TABLET, EXTENDED RELEASE;ORAL	021269-002	Feb 22, 2005
Pfizer	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-002	Nov 2, 1990
Pfizer	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-003	Nov 2, 1990

  Purchase this report

see a sample report or, see our see our flat-rate plans